Referanser

1. Zang YC, J Neuroimmunology 2001;112:174-180

2. Waubant E, J Interferon Cytokine Res 2001;21:181-185

3. Lou J, Lab Invest 1999;79

4. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 1999;5:48-57

5. Rudick RA, Fisher E, Lee J-C, Simon J, Jacobs L, and the Multiple Sclerosis Collaborative Research Group. Use of brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 1999;53:1698-1704

6. Lyon-Caen O, Jouvent R, Hauser S, et al. Cognitive function in recent-onset demyelinating diseases. Arch Neurol. 1986;43:1138-1141.

7. Comi G, Martinelli V, Locatelli T, Leocani L, Medaglini S. Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. Mult Scler. 1998;4:260-265.

8. McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler. 1996;2:198-205.

9. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med. 1997;337:1604-1611.

10. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995;1:37-47.

11. Rao SM, Hammeke TA, McQuillen MP, Khatri BO, Lloyd D. Memory disturbance in chronic progressive multiple sclerosis. Arch Neurol. 1984;41;625-631.

12. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430-1438.

13. Jacobs LD, Cookfair DL, Rudick RA, et al, and the Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.

14. Ellison GW, Myers LW, Leake BD, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol. 1994;36:S108-S112.

15. Goodkin DE, Priore RL, Wende KE, et al, and the Multiple Sclerosis Collaborative Research Group. Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. Mult Scler. 1998;4:480-486.

16. Vermersch P, 14. Vermersch P, de Seze J, Stojkovic T, Hautecoeur P, on behalf of the G-SEP (Groupe Septentrional d'Etudes et de Recherches sur la SEP). Interferon ß-1a (AVONEX ¨ ) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. Eur J Neurol. In press.

17. Hohol MJ, Guttmann CRG, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997;54:1018-1025.

18. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989;39:161-166.

19. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991;29:548-555.

20. Simon JH, Lull J, Jacobs LD, et al, and the Multiple Sclerosis Collaborative Research Group. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon o -1a. Neurology. 2000;55:185-192.

21. Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain. 1991;114: 1013-1023.

22. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion: a quantitative MRI and electron microscopic study. Brain. 1991;114:1271-1280.

23. van Waesberghe JH, Castelijns JA, Scheltens P, et al. Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. Magn Reson Imaging. 1997;15:155-162.

24. van Walderveen, Barkhof F, Pouwels PJW, et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol. 1999;46:79-87.

25. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995;45:255-260.

26. Data on file, Biogen, Inc.

27. Munschauer FE III, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther. 1997;19:883-893.

28. AVONEX^® Prescribing Information.

29. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (AVONEX®) treatment in multiple sclerosis. Int J MS Care [serial online]. Dec 1999;2:1-8.

30. Taylor Nelson Sofres Healthcare. MS Patient Study 2000.
 

31. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.

32. IMS Monthly Xponent data for 12 months ending October 2000.

33. Ross.C et al and the Danish Multiple Study Group. Immunogenecity of Interrferon-ß in Multiple Sclerosis Patients: Influence of Preparation, Dose frequency and Route of Administration, Ann Neurology, 2000;48:706-712

34. Zivadinov R et al. A longitudinal study of brain atrophy and cognitive distyrbances in the early phase of relapsing-remitting multiple sclerosis J Neurol Neurosurg Psychiatry 2001;70;773-780

35. Fischer et al. Neuropsychological Effects of Interferon ß- 1a in Relapsing Multiple Sclerosis. Ann of Neurol 2000; 48:885-892

36. Kinkel, R on behalf of the CHAMPS study group. The effekt of AVONEX in patients with a single demyelinating event and MRI evidence of high lesion burden and active inflammation. J Neurol. 2002;249:1/61

37. Data on file; Jacobs LD: Phase III Pivotal trial, Biogen,Inc

38. Clanet M, Radue EW, Kappos L, et al and the European IFNß-1a (AVONEX) Dose-comparison Study Investigators. A randomized, double-blind,dose-comparison study of weekly interferon beta-1a (AVONEX) in relapsing MS. Neurology 2002; 59: 1507

39. Jacobs LD et al and the CHAMPS study group. Intramuscular Interferon Beta 1a Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis. The N.E Journal of Medicine 2000; Vol 343;13;898-904

40. McDonald I, et al Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis, Annals of Neurology 2001

41. Jacobs L.D. et al. Multiple Sclerosis 1995; (1): 118 - 135

42. Mariani C, Farina E, et al. Neuropsychological assessment in multiple sclerosis; a follow up study with magnetic resonance imaging. J Neurol 1991; 238:395-400

43. Environics Research Group, Survey of MS patients, February to March, 2002, Canada

44. Antonios Bayas: Drug Safety 2000, Feb; 22 (2): 149-159

45. E U Walther; Neurology, Nov 1999; 53 (149-159)

46. The IFNß Multiple Sclerosis Study Group. Interferon beta 1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial Neurology 1993; 43:655-661

47. PRISMS Study Group. Randomized, double-blind, placebo controlled study of interferon beta 1a in relapsing remitting multiple sclerosis, Lancet 1998; 352: 1498-504

48. H. Panitch, D.S. Goodin, et al, for the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group Randomized, comparative study of interferon {beta}-1a treatment regimens in MS: The EVIDENCE Trial Neurology 2002; 59: 1496

49. The PRISMS study Group, and the university of Columbia MS/MRI Analysis Group.PRISMS-4: Long-term efficacy of interferon- 1a in relapsing MS, Neurology 2001; 56:1628-1636

50. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272, 1998.

51. Galetta S L, Markowitz C, Lee A; Immunmodalatory agents for the Treatment of Relapsing Multiple Sclerosis; A systematic review. Arch Intern Med. 2002;162:2161-2169

52. Confavreux C,et al. Relapses and progression of disability in multiple sclerosis. N.Engl.J.Med. 2000;343:1430-1438

53. Kappos L, Clanet M, and the European Interferonbeta-1a (AVONEX) Dose-Comparison Study Group. Sustained efficacy of interferon beta-1a in relapsing multiple sclerosis; 4-year results from the European dose-comparison study. Poster presented at 54th Annual Meeting of the American Academy of Neurology; April 13-20 2002; Denver,Colorado,USA

54. Bertolotto A, J Neurol Neurosurg Psychiatry 2002;73:148-153

55. Freitag P, ECTRIMS 2001, abstract. European Study Group Multiple Sclerosis 2001:7:179-83